| TRAITEMENT |
| Temsirolimus IV | 25 mg/semaine hebdomadaire |
- Nausées/vomissements: risque faible
- Contexte : métastatique
| TOXICITES |
| Toxicités hématologiques | |
| Neutropénie (grade 3/4) | 7% (3%) |
| Anémie (grade 3/4) | 45 % (20%) |
| Thrombopénie (grade 3/4) | 14% (1%) |
| Hypercholestérolémie (grade 3/4) | 24% (1%) |
| Hyperlipidémie (grade 3/4) | 27% (3%) |
| Hyperglycémie (grade 3/4) | 27% (2%) |
| Toxicités non hématologiques | |
| Fatigue (grade 3/4) | 51% (11%) |
| Mucite (grade 3/4) | 20% (1%) |
| Diarrhée (grade 3/4) | 27% (1%) |
| Rash (grade 3/4) | 47% (4%) |